AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6815282 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (single dose on day 3 of illness)
Number of subjects: 20
Study 31769619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-Family DSME (in-home setting)
Number of subjects: 221
Study 31769619 — intervention group
Group type: COMPARATOR
Intervention: Standard DSME (community setting)
Number of subjects: 221
Study 31817816 — intervention group
Group type: EXPERIMENTAL
Intervention: six 30 s one‐on‐one SSGs with a 2 min rest period
Number of subjects: 18
Study 31817816 — intervention group
Group type: EXPERIMENTAL
Intervention: six 45 s SSGs with a 3 min rest interval
Number of subjects: 18
Study 28742420 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized orthodontic system (Insignia)
Number of subjects: 180
Study 28742420 — intervention group
Group type: COMPARATOR
Intervention: Noncustomized orthodontic system (Damon Q)
Number of subjects: 180
Study 27596360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (75 μg/kg/day)
Number of subjects: 72
Study 27596360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27596360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 72
Study 24401729 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-linked tablet computer-based intervention (the EDGE platform)
Number of subjects: 0
Study 24401729 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21993878 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ (conditioned stimulus paired with alcohol intoxication)
Number of subjects: 14
Study 21993878 — intervention group
Group type: COMPARATOR
Intervention: CS- (conditioned stimulus not paired with alcohol intoxication)
Number of subjects: 14
Study 19444413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 28
Study 19444413 — intervention group
Group type: COMPARATOR
Intervention: No propofol therapy
Number of subjects: 28
Study 17536071 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 34
Study 17536071 — intervention group
Group type: COMPARATOR
Intervention: Diane(35) Diario (35 microg ethinyl-estradiol plus 2 mg cyproterone acetate)
Number of subjects: 34
Study 15350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 2500 U, 2500 U, 5000 U, and 7500 U daily
Number of subjects: 15
Study 15350250 — intervention group
Group type: COMPARATOR
Intervention: UFH 5000 U, 5000 U, 7500 U, and 10,000 U every 12 hours
Number of subjects: 15
Study 11772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate diabetes lifestyle intervention in family and friends (FF) groups (n = 32)
Number of subjects: 104
Study 11772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate diabetes lifestyle intervention in one-on-one (OO) appointments (n = 39)
Number of subjects: 104
Study 11772905 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UC) (n = 33)
Number of subjects: 104
Study 11772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention arms (FF and OO)
Number of subjects: 104
Study 9694068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan levels in the synovium of patients with rheumatoid arthritis (RA)
Number of subjects: 0
Study 9694068 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronan levels in the synovium of patients with osteoarthritis
Number of subjects: 0
Study 9694068 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronan levels in the synovium of patients with traumatic injury
Number of subjects: 0
Study 7521490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (0.1 mg/kg in 20 min)
Number of subjects: 13
Study 7521490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl infusion)
Number of subjects: 13
Study 2589674 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of agitated saline via a peripheral vein
Number of subjects: 33
Study 2589674 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of air via the epidural catheter
Number of subjects: 33
Study 2589674 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (nothing injected)
Number of subjects: 33
Study 2589674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of air via catheters accidentally inserted in epidural veins
Number of subjects: 33
Study 790358 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefarnate, 50 mg four times daily
Number of subjects: 45
Study 790358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dummy capsules)
Number of subjects: 45
Study 30366235 — intervention group
Group type: EXPERIMENTAL
Intervention: EF/PS CCT
Number of subjects: 46
Study 30366235 — intervention group
Group type: COMPARATOR
Intervention: Verbal ability CCT
Number of subjects: 46
Study 30366235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 28151991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic profiling with clinical decision support tool (CDST)
Number of subjects: 110
Study 28151991 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 110
Study 25307511 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol therapy
Number of subjects: 48
Study 25307511 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 48
Study 23404304 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 262
Study 23404304 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 262
Study 23404304 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (aerobic + resistance)
Number of subjects: 262
Study 23404304 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 262
Study 20826742 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 24
Study 20826742 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 19514184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent-turtle massage
Number of subjects: 182
Study 19514184 — intervention group
Group type: COMPARATOR
Intervention: Conventional massage method
Number of subjects: 182
Study 17695213 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trial
Number of subjects: 1
Study 14693964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60
Study 14693964 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60
Study 14693964 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 60
Study 11641676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg) every 6 hours
Number of subjects: 126
Study 11641676 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (50 microg) every 3 hours
Number of subjects: 126
Study 9408917 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 +/‐ 2.5 mg/day
Number of subjects: 335
Study 9408917 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 +/‐ 2.5 mg/day
Number of subjects: 335
Study 9408917 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 +/‐ 2.5 mg/day
Number of subjects: 335
Study 9408917 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 15 +/‐ 5 mg/day
Number of subjects: 335
Study 9408917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 8208968 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based (video) informed consent
Number of subjects: 160
Study 8208968 — intervention group
Group type: COMPARATOR
Intervention: Written informed consent
Number of subjects: 160
Study 2543996 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 30
Study 2543996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30626400 — intervention group
Group type: EXPERIMENTAL
Intervention: P3P (Personal Patient Profile‐Prostate)
Number of subjects: 392
Study 30626400 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 392
Study 27856067 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL Retaining (PCLR) TKA
Number of subjects: 37
Study 27856067 — intervention group
Group type: COMPARATOR
Intervention: PCL Substituting (PCLS) TKA
Number of subjects: 37
Study 26141466 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 15.0 g/d
Number of subjects: 245
Study 23718222 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish Diabetes Self-Management Program (SDSMP)
Number of subjects: 0
Study 23718222 — intervention group
Group type: COMPARATOR
Intervention: Usual care according to clinical guidelines for DM2
Number of subjects: 0
Study 21189274 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal food intake
Number of subjects: 58434
Study 19317163 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyu Zhixue Tablet (XYZXT)
Number of subjects: 98
Study 19317163 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (adrenosin, vitamins C, K and P)
Number of subjects: 98
Study 14510743 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (1 g)
Number of subjects: 13
Study 14510743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10424639 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1155
Study 10424639 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1155
Study 7784148 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 intraarterial subtraction angiography (IADSA) in group A (proper hepatic artery)
Number of subjects: 31
Study 7784148 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 intraarterial subtraction angiography (IADSA) in group B (segmental hepatic artery)
Number of subjects: 31
Study 7784148 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 intraarterial subtraction angiography (IADSA) in group C (peripheral inferior phrenic artery)
Number of subjects: 31
Study 2162270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity transcutaneous electrical stimulation (homolateral)
Number of subjects: 29
Study 2162270 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity transcutaneous electrical stimulation (ipsilateral)
Number of subjects: 29
Study 2162270 — intervention group
Group type: COMPARATOR
Intervention: High-intensity transcutaneous electrical stimulation (contralateral)
Number of subjects: 29
Study 2162270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity transcutaneous electrical stimulation (homolateral) during homatropine blockade
Number of subjects: 29
Study 442223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Methotrexate + Fluorouracil (CMF) chemotherapy
Number of subjects: 15
Study 442223 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients operated on for breast cancer and in spontaneous menopause)
Number of subjects: 15
Study 31983539 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and obese children
Number of subjects: 200
Study 31983539 — intervention group
Group type: COMPARATOR
Intervention: Lean counterparts
Number of subjects: 200
Study 29893462 — intervention group
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX (400/100/100 mg) daily for 12 weeks
Number of subjects: 147
Study 29893462 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving SVR
Number of subjects: 147
Study 29893462 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 147
Study 28374512 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (SAL) via two different dry powder inhalers
Number of subjects: 45
Study 28374512 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (SAL)
Number of subjects: 45
Study 26402859 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (High-Intensity Interval Training)
Number of subjects: 90
Study 26402859 — intervention group
Group type: COMPARATOR
Intervention: MICT (Moderate-Intensity Continuous Training)
Number of subjects: 90
Study 23511248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrite and nitrate concentrations in heparinized plasma
Number of subjects: 16
Study 23511248 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of nitrite between plasma and erythrocytes
Number of subjects: 16
Study 23511248 — intervention group
Group type: COMPARATOR
Intervention: Plasma nitrite and nitrate concentrations in rabbit model of ARDS
Number of subjects: 16
Study 21160466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 48
Study 21160466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with paired associative stimulation (PAS)
Number of subjects: 48
Study 21160466 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 48
Study 21160466 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches combined with paired associative stimulation (PAS)
Number of subjects: 48
Study 19625549 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound
Number of subjects: 800
Study 17785028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telemonitoring programme
Number of subjects: 55
Study 15173543 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE program (educational-behavioral intervention)
Number of subjects: 163
Study 15173543 — intervention group
Group type: COMPARATOR
Intervention: Control group (structurally equivalent control program)
Number of subjects: 163
Study 11493491 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual traction with Duval's forceps
Number of subjects: 30
Study 11493491 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw thrust
Number of subjects: 30
Study 11493491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined jaw thrust and lingual traction
Number of subjects: 30
Study 11493491 — intervention group
Group type: COMPARATOR
Intervention: Jaw thrust and lingual traction used alone
Number of subjects: 30
Study 9761804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 microg, 2.5 ml) with albuterol
Number of subjects: 434
Study 7822626 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter present
Number of subjects: 0
Study 7822626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother present
Number of subjects: 0
Study 7822626 — intervention group
Group type: EXPERIMENTAL
Intervention: Alone
Number of subjects: 0
Study 7822626 — intervention group
Group type: COMPARATOR
Intervention: Control (normal boys)
Number of subjects: 0
Study 31464975 — intervention group
Group type: EXPERIMENTAL
Intervention: Municipal rehabilitation starting 4 to 6 weeks postoperative
Number of subjects: 146
Study 31464975 — intervention group
Group type: COMPARATOR
Intervention: No referral to rehabilitation (HOME group)
Number of subjects: 146
Study 30419855 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital nerve field stimulation (ONS), active stimulation condition (ON)
Number of subjects: 7
Study 30419855 — intervention group
Group type: COMPARATOR
Intervention: Occipital nerve field stimulation (ONS), no stimulation condition (OFF)
Number of subjects: 7
Study 27429036 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific virtual reality rehearsal (PsR) before EVAR
Number of subjects: 100
Study 27429036 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no PsR)
Number of subjects: 100
Study 25010358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-type breakfast
Number of subjects: 16
Study 25010358 — intervention group
Group type: COMPARATOR
Intervention: Western-type breakfast
Number of subjects: 16
Study 22652468 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF hydrogel (GC group, n=32)
Number of subjects: 65
Study 22652468 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel without rhGM‐CSF (control group, n=33)
Number of subjects: 65
Study 20171529 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipurpose exercise program (n=123)
Number of subjects: 246
Study 20171529 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n=123)
Number of subjects: 246
Study 19380203 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac (TDiclo)
Number of subjects: 775
Study 19380203 — intervention group
Group type: COMPARATOR
Intervention: DMSO vehicle
Number of subjects: 775
Study 19380203 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac (ODiclo)
Number of subjects: 775
Study 19380203 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac (TDiclo) + Oral diclofenac (ODiclo)
Number of subjects: 775
Study 16412870 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TEX)
Number of subjects: 26
Study 16412870 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole stress
Number of subjects: 26
Study 15286220 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic amino acid (IAA) solution
Number of subjects: 44
Study 15286220 — intervention group
Group type: COMPARATOR
Intervention: 0.25 normal saline (NS) solution
Number of subjects: 44
Study 11389239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy-tube placement (TTP)
Number of subjects: 173
Study 9240892 — intervention group
Group type: EXPERIMENTAL
Intervention: Low selenium state in patients with phenylketonuria
Number of subjects: 87
Study 8237799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 7E3 (0.1 mg/kg [n = 5], 0.2 mg/kg [n = 22], 0.15 mg/kg [n = 13], 0.25 mg/kg [n = 20])
Number of subjects: 124
Study 8237799 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric 7E3 bolus (up to 0.25 mg/kg) with intravenous continuous infusion of 7E3 (10 micrograms/min for 6 to 24 hours)
Number of subjects: 124
Study 8237799 — intervention group
Group type: COMPARATOR
Intervention: Chimeric 7E3 bolus (up to 0.25 mg/kg) without intravenous continuous infusion of 7E3
Number of subjects: 124
Study 3684122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (50 mg intramuscular injection)
Number of subjects: 54
Study 3684122 — intervention group
Group type: COMPARATOR
Intervention: Estandron prolongatum (estradiol/testosterone ester combination, single intramuscular dose)
Number of subjects: 54
Study 3684122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 54
Study 28688001 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir 400 mg + Pibrentasvir 120 mg
Number of subjects: 72
Study 28688001 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir 700 mg + Pibrentasvir 160 mg
Number of subjects: 72
Study 28688001 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir (100-1200 mg) + Pibrentasvir (40-200 mg)
Number of subjects: 72
Study 28688001 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir (700 and 1200 mg)
Number of subjects: 72
Study 28688001 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir up to 400 mg + Pibrentasvir
Number of subjects: 72
Study 27149646 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic aspirin use (1274 women)
Number of subjects: 2925
Study 27149646 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic aspirin use among lymph node-negative tumors
Number of subjects: 2925
Study 27149646 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic aspirin use among lymph node-positive tumors
Number of subjects: 2925
Study 24060449 — intervention group
Group type: EXPERIMENTAL
Intervention: PA plus D (physical activity and dietary intervention)
Number of subjects: 425
Study 24060449 — intervention group
Group type: EXPERIMENTAL
Intervention: PA (physical activity intervention)
Number of subjects: 425
Study 24060449 — intervention group
Group type: COMPARATOR
Intervention: C (control group receiving standard care)
Number of subjects: 425
Study 24060449 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (combined analysis)
Number of subjects: 425
Study 22315329 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium-sugammadex (1 mg kg(‐1) rocuronium and 16 mg kg(‐1) sugammadex)
Number of subjects: 61
Study 22315329 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg kg(‐1))
Number of subjects: 61
Study 20537843 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Changes (SC)
Number of subjects: 52
Study 20537843 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Changes (LC)
Number of subjects: 52
Study 18334283 — intervention group
Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 142
Study 18334283 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pain intensity on VAS
Number of subjects: 142
Study 18334283 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher disability on RDQ
Number of subjects: 142
Study 15950492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 30 days
Number of subjects: 19
Study 15950492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12637609 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106
Study 12637609 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa plus low-dose cytarabine
Number of subjects: 1106
Study 10700786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenoxicam (40 mg before surgery, 20 mg orally for 8 days)
Number of subjects: 101
Study 10700786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (40 mg after surgery, 40 mg i.v. at 24 h after surgery)
Number of subjects: 101
Study 10700786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8739173 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO probe tine at 0.25 N
Number of subjects: 12
Study 8739173 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO probe tine at 0.5 N
Number of subjects: 12
Study 8739173 — intervention group
Group type: COMPARATOR
Intervention: Parallel-sided tine at 0.25 N
Number of subjects: 12
Study 8739173 — intervention group
Group type: COMPARATOR
Intervention: Parallel-sided tine at 0.5 N
Number of subjects: 12
Study 8739173 — intervention group
Group type: COMPARATOR
Intervention: Tapered tine at 0.25 N
Number of subjects: 12
Study 8739173 — intervention group
Group type: COMPARATOR
Intervention: Tapered tine at 0.5 N
Number of subjects: 12